FDA Inspection 1288372 — Exeltis Pharmaceuticals, Inc.
The FDA completed an inspection of Exeltis Pharmaceuticals, Inc. on Jul 3, 2025 in Tekirdag. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Jul 3, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Tekirdag (Turkey)
Additional details
Bioanalytical BA/BE